Thalassemia Diagnostic Market to to Grow with a CAGR of 5.41% through 2030
Advancements in diagnostic technologies and growing awareness
about thalassemia is expected to drive the global thalassemia diagnostic market
in the forecast period 2026-2030.
According to the TechSci Research
report, “Thalassemia Diagnostic
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
2030F”, Global Thalassemia Diagnostic Market stood at USD 654.11 million in 2024 and is anticipated to grow with a CAGR of 5.41% in the forecast period through 2030. Individuals with thalassemia
produce fewer healthy red blood cells and are therefore at a higher risk of
developing anemia, fatigue, and other complications. The disorder is
particularly prevalent in countries around the Mediterranean, Middle East, and
Asia, where the gene mutations are more common. The, supportive government
policies in these countries have played a significant role in influencing the
demand for the global thalassemia diagnostic market. Governments have invested
in research and development, provided funding to increase access to diagnostic
tests, implemented policies for mandatory screening, and launched awareness
campaigns to increase understanding about the disorder. These efforts have led
to an increase in the demand for thalassemia diagnostic tests and have helped
to improve the quality of care for individuals with thalassemia. Apart from
these, the growing awareness about thalassemia has led to an increase in the
demand for thalassemia diagnostic tests. Diagnostic tests for thalassemia
include blood tests, DNA analysis, and hemoglobin electrophoresis. These tests
are used to screen, diagnose, and monitor the disease. As more people seek
diagnostic tests for thalassemia, the demand for thalassemia diagnostic tests
is expected to continue to grow.
While advancements in diagnostic
technologies have greatly improved the detection and management of thalassemia,
there are still challenges that need to be addressed such as cost of diagnostic
tests, access to diagnostic tests, accuracy of diagnostic tests, interpretation
of test results, and standardization of diagnostic tests. In many parts of the
world, access to diagnostic tests for thalassemia is limited. This can result
in delayed or inaccurate diagnosis, and a lack of proper management and
treatment for affected individuals, thereby hampering the growth of global
thalassemia diagnostics market. At the same time, some of the advanced diagnostic technologies
used for thalassemia, such as genetic testing, can be expensive. This can be a
barrier to accessing these tests, particularly in low-income areas or
countries. Therefore, all the above factor is expected to impend the growth of thalassemia
diagnostic market.
Browse over XX market data
Figures spread through XX Pages and an in-depth TOC on the "Global Thalassemia Diagnostic Market"
Global thalassemia diagnostic market is
segmented based on type, end-user, regional distribution and company.
Based on Type, DNA tests is expected to exhibit the fastest compound annual growth rate (CAGR) in the coming years due to growing demand for accurate, prenatal, and carrier diagnostics. DNA tests offer a definitive diagnosis of specific genetic mutations responsible for various types of thalassemia, including alpha and beta thalassemia. Unlike CBC and hemoglobin electrophoresis, which are indirect, DNA testing allows direct identification of thalassemia genes, making it critical for preimplantation genetic diagnosis, prenatal screening, and family planning. The rise in awareness about inherited disorders, increasing government focus on genetic screening, and the growing demand for personalized medicine are all contributing to the segment's rapid expansion. In countries like China, Thailand, and India—where thalassemia is highly prevalent—governments and non-profit organizations are promoting molecular-level diagnostics, particularly for at-risk couples.
Based on the Region, Asia Pacific is emerging as the fastest-growing region in the global thalassemia diagnostic market. This rapid growth is driven by the high prevalence of thalassemia across countries such as India, China, Thailand, Indonesia, and Malaysia—regions where a significant portion of the population carries genetic mutations associated with hemoglobin disorders. According to the World Health Organization (WHO), Southeast Asia bears one of the highest global burdens of thalassemia, with an estimated carrier rate ranging between 3% and 15% in various countries. In India alone, more than 10,000 children are born annually with thalassemia major, underscoring the urgent need for robust diagnostic strategies. Governments in the Asia Pacific region are increasingly recognizing thalassemia as a public health concern and have initiated screening and prevention programs to curb the birth rate of affected individuals. For instance, Thailand has implemented a national thalassemia prevention and control program that includes carrier screening, prenatal diagnosis, and public education campaigns. Similarly, India’s Ministry of Health has integrated hemoglobinopathy screening into public health initiatives such as the Rashtriya Bal Swasthya Karyakram (RBSK), which aims to screen newborns and school-aged children for inherited disorders.
Major companies operating in the global thalassemia
diagnostic market are:
- Hybribio Limited
- Oasis Diagnostics Corporation
- ViennaLab Diagnostics GmbH
- GENETEK BIOPHARMA GmbH
- Devyser Diagnostics AB
- YANENG BIOSCIENCE (SHENZHEN) CO.,LTD.
- BioLab Diagnostics India Private Limited
- NPT Co. Ltd.
- Bio-Rad Laboratories, Inc.
- Chiesi Farmaceutici S.p.A
Download Free Sample Report
Customers can also request for 10% free
customization on this report.
“Global thalassemia
diagnostics market is experiencing growth due to several factors, including
increasing prevalence of thalassemia, rising awareness and screening programs,
and supportive government policies. Thalassemia is a genetic blood disorder
that affects the production of hemoglobin and can lead to anemia, organ damage,
and other serious complications. As awareness of the disorder increases, more
individuals are being screened for thalassemia, leading to an increased demand
for diagnostic tests. Furthermore, advancements in diagnostic technologies have
also contributed to the growth of the thalassemia diagnostics market. Genetic
testing, point-of-care testing, molecular and cellular technologies, imaging
technologies, and liquid biopsy are among the most significant advancements
that have improved the sensitivity and accuracy of diagnostic tests for
thalassemia. These technologies have also enabled early detection and
monitoring of the disorder, which is crucial for proper management and
treatment of Top of Formthalassemia
are likely to benefit from the market growth and create huge prospects of thalassemia
diagnostic market growth during the forecast period,” said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based global management
consulting firm.
“Thalassemia Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Complete Blood Cell (CBC) Test, Hemoglobin Test, Iron Deficiency Test, DNA Tests, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region and Competition, 2020-2030F", has evaluated the future
growth potential of global thalassemia diagnostic market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in the global thalassemia diagnostic market.”
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com